Compare Ascendis Pharma A/S (ASND) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Futu Holdings Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Futu Holdings Ltd trades at $95.45 (market cap $13.51B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Futu Holdings Ltd pays a 2.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | FUTU | |
|---|---|---|
Market Cap | $17.74B | $13.51B |
Sector | Health | Financials |
52-Week High | $277.18 | $199.04 |
52-Week Low | $163.32 | $89.76 |
Enterprise Value | $18.11B | $13.36B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Futu Holdings trades at $96.33, down 0.71% on the day, with a neutral technical signal and key support at $95. The company reported strong 2025 revenue of $22.85 billion and net income of $11.34 billion, with high profitability margins. However, recent earnings misses and a securities class action lawsuit have introduced uncertainty.
The outlook is mixed: solid fundamentals and a 'Buy' analyst consensus support upside, but legal risks and earnings volatility pose significant headwinds. Investors should weigh the attractive valuation against potential regulatory and litigation overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
